Effects of Hypogonadism and Testosterone Administration on Depression Indices in HIV-Infected Men1
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Hypogonadism is prevalent among human immunodeficiency virus-infected men, in whom significantly reduced quality of life and mood disturbances have been reported. Previous studies have not investigated the relationship between depression score and gonadal function among such patients. We first compared depression scores in hypogonadal (n = 52) and eugonadal (n = 10) patients with acquired immunodeficiency syndrome (AIDS) wasting, matched for weight and disease status, and then investigated the effects of testosterone administration on depression score in a randomized, double-blind, placebo-controlled study among the group of hypogonadal men with AIDS wasting. The primary end point in all comparisons was the Beck Depression Inventory. Hypogonadal patients demonstrated significantly increased scores on the Beck inventory compared with eugonadal-, age-, weight-, and disease status-matched subjects (15.5+/-1.1 vs. 10.6+/-1.4 mean +/- SEM, P = 0.02). Among the combined hypogonadal and eugonadal subjects, a significant inverse correlation was seen between the Beck score and both free (r = 0.41, P<0.01) and total serum testosterone levels (r = -0.43, P<0.001). The relationship between the Beck score and testosterone levels remained highly significant, controlling for weight, viral load, CD4 count, and antidepressant use (P<0.01 for free testosterone, P<0.001 for total testosterone). Furthermore, when subjects were divided into two groups, based on a Beck score greater than 18 or less than or equal to 18, serum total and free testosterone levels were significantly lower in the subjects with a Beck score greater than 18, whereas there were no differences in weight, viral load, CD4 count, or Karnofsky status. End of study data were available in 39 patients who completed the randomized, placebo-controlled study. Beck score decreased significantly only in the subjects receiving testosterone (-5.8+/-1.3, P< 0.001), but not in subjects randomized to placebo (-2.7+/-1.3, P> 0.05). In a regression analysis, the change in Beck score was related significantly to change in weight (P<0.01). These data demonstrate increased depression score in association with hypogonadism in men with AIDS wasting, independent of weight, virologic status, and other disease factors. In such patients, administration of testosterone results in a significant improvement in depression inventory score. This effect may be a direct effect of testosterone or related to positive effects of testosterone on weight and/or other anthropometric indices. Additional studies are needed to assess the effects of testosterone on clinical depression indices in human immunodeficiency virus-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioavailable Testosterone and Depressed Mood in Older Men: The Rancho Bernardo Study
Barrett-Connor, E., von Mühlen, D. G., & Kritz-Silverstein, D. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5495 · Cited by 472 · cited 2×
“(4) in non-HIV-infected men, in which the Beck Depression Inventory was also used as a primary end point.”
BackgroundMethodBURRIS, A. S., BANKS, S. M., CARTER, C. S., DAVIDSON, J. M., & SHERINS, R. J. (1992) · Journal of Andrology · doi:10.1002/j.1939-4640.1992.tb00319.x · Cited by 259 · cited 2×
“Antidepressant use in the hypogonadal men included amitryptiline (2), imipramine (1), doxepin (1), fluoxitene (2), nefazadone (3), and sertraline (2) at baseline.”
BackgroundThe analog free testosterone assay: are the results in men clinically useful?
Winters, S. J., Kelley, D. E., & Goodpaster, B. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.10.2178 · Cited by 160
Cited by
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Andropause: clinical implications of the decline in serum testosterone levels with aging in men
Matsumoto, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.2.m76 · Cited by 490
Testosterone and Depression: Systematic Review and Meta-Analysis
Zarrouf, F. A., Artz, S., Griffith, J., Sirbu, C., & Kommor, M. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000358315.88931.fc · Cited by 383
The benefits and risks of testosterone replacement therapy: a review
Morley, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 369
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Pope, H. G., Cohane, G. H., Kanayama, G., Siegel, A. J., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.105 · Cited by 341
HIV and Depression – a systematic review of interventions
Sherr, L., Clucas, C., Harding, R., Sibley, E., & Catalan, J. (2011) · Psychology, Health & Medicine · doi:10.1080/13548506.2011.579990 · Cited by 325
“…(1996); Clifford et al. (2005); Elliott et al. (1998); Erlen et al. (2001); Fukunishi et al. (1997); Gonzáles, Munoz, PerezArce, and Batki (1993); Grinspoon et al. (2000); Hawkins et al. (2005); Hinkin et al. (2001); Hintz, Kuck, Peterkin, Volk, and Zisook 1990; Husbands et al. (2007);…”
InfluentialBhasin, S., Calof, O. M., Storer, T. W., Lee, M. L., Mazer, N. A., Jasuja, R., Montori, V. M., Gao, W., & Dalton, J. T. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0120 · Cited by 300
Hormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer, J. B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C. I., Carpenter, L. L., Nemeroff, C. B., McDonald, W. M., Kalin, N. H., & APA Council of Research Task Force on Novel Biomarkers and Treatments (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080848 · Cited by 252
Illicit anabolic–androgenic steroid use
Kanayama, G., Hudson, J. I., & Pope, H. G. (2010) · Hormones and Behavior · doi:10.1016/j.yhbeh.2009.09.006 · Cited by 257
Increased Incidence of Diagnosed Depressive Illness in HypogonadalOlder Men
Shores, M. M., Sloan, K. L., Matsumoto, A. M., Moceri, V. M., Felker, B., & Kivlahan, D. R. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.2.162 · Cited by 243
Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids
Rajagopal, A., Vassilopoulou‐Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2004) · Cancer · doi:10.1002/cncr.20028 · Cited by 206
“In one study of patients with acquired immunodeficiency syndrome, there was a clear association between hypogonadism and the development of significant depression.(45) These patients were not in pain and were not consuming opioids but had developed hypogonadism from other causes.”
BackgroundSarcopenia During Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L. J., Ke, C., Leder, B. Z., & Goessl, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8850 · Cited by 196
Almeida, O. P., Yeap, B. B., Hankey, G. J., Jamrozik, K., & Flicker, L. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.33 · Cited by 158
Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency
Daniell, H. W., Lentz, R., & Mazer, N. A. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2005.10.009 · Cited by 135
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Andropause: is androgen replacement therapy indicated for the aging male?
Hijazi, R. A., & Cunningham, G. R. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104518 · Cited by 105
Treatment of Men for “Low Testosterone”: A Systematic Review
Huo, S., Scialli, A. R., McGarvey, S., Hill, E., Tügertimur, B., Hogenmiller, A., Hirsch, A. I., & Fugh-Berman, A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162480 · Cited by 97
Pope, H. G., Amiaz, R., Brennan, B. P., Orr, G., Weiser, M., Kelly, J. F., Kanayama, G., Siegel, A., Hudson, J. I., & Seidman, S. N. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d207ca · Cited by 90
Metadata
- Authors
- Grinspoon, S., Corcoran, C., Stanley, T., Baaj, A., Basgoz, N., & Klibanski, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-01
- Volume
- 85
- Issue
- 1
- Pages
- 60-65
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2099393002
- Cited by
- 138
- References
- 3
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.